IL10 and visceral leishmaniasis: On the other hand, mAbs targeting both cutaneous as well as visceral leishmaniasis caused by the Leishmania parasites, have been studied preclinically over the last years (Supplementary file), and there is even a mAbs in de clinical stage targeting IL10 (anti IL-10, SCH708980, NCT01437020) which may help to prevent the immune system from becoming suppressed and worsening the disease in combination with standard therapy.